Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Combination vaccines in the South African setting.

Visser A, Hoosen A.

Vaccine. 2012 Sep 7;30 Suppl 3:C38-44. doi: 10.1016/j.vaccine.2012.05.001. Review.

PMID:
22939020
2.

Haemophilus influenzae type b conjugate vaccines - a South African perspective.

Visser A, Hoosen A.

Vaccine. 2012 Sep 7;30 Suppl 3:C52-7. doi: 10.1016/j.vaccine.2012.06.022. Review.

PMID:
22939022
4.
7.

Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.

Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L; Spanish DTaP-HBV-IPV-097 Study Group.

Pediatr Infect Dis J. 2006 Aug;25(8):713-20.

PMID:
16874171
8.
9.

Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.

Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.

Vaccine. 2009 Apr 28;27(19):2540-7. doi: 10.1016/j.vaccine.2008.11.115. Epub 2009 Jan 3.

PMID:
19124057
10.

Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.

Halperin SA, Langley JM, Hesley TM, Zappacosta PS, Radley D, Smith B, Hoffenbach A, Boslego J, Silber JL.

Hum Vaccin. 2005 Nov-Dec;1(6):245-50. Epub 2005 Nov 17.

PMID:
17012871
11.

Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.

Schmitt HJ, von Kries R, Hassenpflug B, Hermann M, Siedler A, Niessing W, Clemens R, Weil J.

Pediatr Infect Dis J. 2001 Aug;20(8):767-74.

PMID:
11734739
13.

New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).

Johns TL, Hutter GE.

Ann Pharmacother. 2010 Mar;44(3):515-23. doi: 10.1345/aph.1M468. Review.

PMID:
20197476
16.
18.

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.

Diaz-Mitoma F, Halperin SA, Tapiero B, Hoffenbach A, Zappacosta PS, Radley D, Bradshaw S, Martin JC, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.

Vaccine. 2011 Feb 1;29(6):1324-31. doi: 10.1016/j.vaccine.2010.11.053. Epub 2010 Dec 4.

PMID:
21134456
19.
20.

Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey.

Hoppenbrouwers K, Kanra G, Roelants M, Ceyhan M, Vandermeulen C, Yurdakök K, Silier T, Dupuy M, Pehlivan T, Ozmert E, Desmyter J.

Vaccine. 1999 Feb 26;17(7-8):875-86.

PMID:
10067694

Supplemental Content

Support Center